Nonalcoholic Steatohepatitis and Liver Transplantation

Current Hepatology Reports - Tập 15 - Trang 113-116 - 2016
Zobair M. Younossi1,2, Linda Henry2
1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, USA
2Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, USA

Tóm tắt

The growing epidemic of obesity has led to an increase in the number of patients developing end-stage liver disease related to nonalcoholic steatohepatitis (NASH). In fact, NASH is now the second-leading etiology for liver transplantation in the USA. In this context, interest is growing in understanding the outcomes of liver transplantation in patients with NASH. Current data suggest that the short- and medium-term outcomes for NASH patients post-transplantation are not different from those for other recipients. Nevertheless, patients with NASH and diabetes may have higher risk post-transplantation for de novo diabetes. Caregivers must be vigilant post-transplant for the development of de novo diabetes regardless of their pre-transplant status. NASH patients also seem to have a lower functional status post-transplant. There are conflicting data regarding the outcome of morbidly obese patients with NASH who undergo liver transplantation. The pre-transplant management of these patients with surgical weight loss is reported, but caution must be exercised in considering them for transplant.

Tài liệu tham khảo

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2015. doi:10.1002/hep.28431. This is the first meta-analysis that has captured the incidence and prevalence of NAFLD worldwide, reporting NAFLD using all methods of diagnosing and only radiologic methods.

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.

Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.

Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106–10.

Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990;85:1349–55.

Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.

Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91:319–27. This is an important study as it brings to everyone’s attention that NAFLD is not just found in the obese population but that it can be manifested in individuals who are not overweight.

Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30. doi:10.1002/hep.28123. This study uses population-level data to demonstrate the linkage of NAFLD and hepatocellular carcinoma as well as reporting the increase in HCC as a result of NAFLD.

Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428–33; quiz e50.

Reddy SK, Steel JL, Chen H-W, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–19.

Su F, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, et al. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes and transplant-related survival benefit. Gastroenterology. 2015. doi:10.1053/j.gastro.2015.10.043. This is a comprehensive article that addresses all aspects of liver transplantation for different liver disease etiologies.

Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55. doi:10.1053/j.gastro.2014.11.039. This article compiles information that demonstrates the increasing clinical burden of NAFLD and as result reports that NASH is now the second leading indication for liver transplantation.

Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–95.

Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with nonalcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant. 2014;28(6):713–21.

Asarnai S, O’Leary J. The changing liver transplant waitlist: an emerging liver purgatory? Gastroenterology. 2015;148(3):493–6. doi:10.1053/j.gastro.2015.01.011. A very engaging article that brings to light many issues that surround liver transplantation such as patient demographics and etiologies of liver disease.

Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(3):394–402.e1. doi: 10.1016/j.cgh.2013.09.023.

Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for nonalcoholic steatohepatitis. BMC Gastroenterol. 2015;15:175. doi:10.1186/s12876-015-0407-.

Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40(6):686–94. doi:10.1111/apt.12881.

Brandman D, Hameed B, Dodge JL, Roberts JP, Terrault NA. Nonalcoholic steatohepatitis (NASH): fittest liver transplantation candidates? Presented at the AASLD meeting. San Francisco, CA; 2015.

Therapondos G, Harper L, Bzowej N, Girgrah N, Joshi S, Bohorquez H, et al. Liver transplantation in the morbidly obese: do the outcomes justify the use of scarce organs? AASLD Poster Presentation, San Francisco, CA; 2015. Abstract.

Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci. 2015;60(10):3142–8. doi:10.1007/s10620-015-3821-7.

VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015. doi:10.1111/liv.12872.

Hussein AA, Elbanna A, Bilasy S, Salama K. Can we avoid liver transplantation in NASH? A novel bypass surgery improves liver condition in NAFLD/NASH patients. AASLD Poster Presentation, San Francisco, CA; 2015. Abstract# 2215.

Uttal S, VanWagner L, Lapin B, Jichlinski A, Lee J, Poole B, et al. Improved but persistent poor functional performance at 1 year after liver transplantation: predictors of performance and opportunities for intervention. AASLD Poster Presentation, San Francisco, CA; 2015. Abstract# 520.

Thông tin
Thông tin xuất bản

Current Hepatology Reports

Tập 15

113-116

Thông tin tác giả